Roivant Sciences Ltd. (ROIV) director nets stock award and tax settlement

Rhea-AI Filing Summary

Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. On January 20, 2026, he received an award of 609 Common Shares under the company’s Non-Employee Director Compensation Plan, which were fully vested on the grant date and recorded at $0 per share as a stock grant. On the same date, 122 Common Shares were withheld and forfeited at $22.98 per share through a net settlement to cover tax withholding obligations tied to the vesting of previously granted shares. After these transactions, he directly owned 109,030 Common Shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider MOMTAZEE JAMES C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	609	$0.00	--
Tax Withholding	Common Shares	122	$22.98	$3K

Holdings After Transaction: Common Shares — 109,152 shares (Direct)

Footnotes (1)

1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOMTAZEE JAMES C

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/20/2026		A		609(1)	A	$0(1)	109,152	D
Common Shares	01/20/2026		F		122(2)	D	$22.98	109,030	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

2. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

	By: /s/ Jo Chen, as Attorney-in-Fact for James C Momtazee	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Roivant Sciences Ltd. (ROIV) report for James C. Momtazee?

The filing shows that director James C. Momtazee received an award of 609 Common Shares and had 122 Common Shares withheld to cover taxes, all on January 20, 2026.

How many Roivant Sciences (ROIV) shares does James C. Momtazee own after this Form 4?

Following the reported transactions, James C. Momtazee directly beneficially owned 109,030 Common Shares of Roivant Sciences Ltd.

What does the 609-share award to the Roivant (ROIV) director represent?

The 609 Common Shares represent a fully vested stock award granted under Roivant Sciences Ltd.’s Non-Employee Director Compensation Plan, recorded at $0 per share as an equity grant.

Why were 122 Roivant Sciences (ROIV) shares forfeited in this Form 4?

The 122 Common Shares were used in a net settlement by the company to satisfy applicable tax withholding obligations related to the vesting and settlement of previously granted shares.

What do the transaction codes A and F mean in this Roivant (ROIV) Form 4?

In this filing, code A refers to an acquisition of 609 Common Shares as a director stock award, and code F reflects shares withheld (122 Common Shares) to cover taxes through net settlement.

Is the ownership reported by James C. Momtazee in Roivant (ROIV) shares direct or indirect?

The Form 4 indicates that after the transactions, James C. Momtazee’s 109,030 Common Shares are held with direct (D) ownership.